The Arrowhead Research Corp (NASDAQ:ARWR) on Mar. 24 announced that patient dosing has begun in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The study is planned to enroll up to 16 chronic HBV patients in two dose cohorts with patients receiving either ARC-520 or placebo in combination with entecavir. The study is designed to evaluate the depth and duration of hepatitis B surface antigen (HBsAg) decline, among other measures, in response to a single dose of ARC-520. Arrowhead Research Corp (NASDAQ:ARWR) shares after opening at $16.30 moved to $16.92 on last trade day and at the end of the day closed at $15.62. Company price to sales ratio in past twelve months was calculated as 7.13 and price to cash ratio as 9.37. Arrowhead Research Corp (NASDAQ:ARWR) showed a negative weekly performance of -24.54%.
Dicerna Pharmaceuticals (NASDAQ:DRNA) saw an uptick in trading volume on Friday after the company announced better than expected quarterly earnings, American Banking & Market News reports. 357,389 shares were traded during mid-day trading, an increase of 103% from the previous session’s volume of 176,045 shares.The stock last traded at $29.05 and had previously closed at $30.61.Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares fell -5.10% in last trading session and ended the day on $29.05. DRNA return on equity ratio is recorded as 54.10% and its return on assets is -125.00%.
Relypsa Inc (NASDAQ:RLYP) , a biopharmaceutical company, reported financial results for the fourth quarter and year ended December 31, 2013.Cash, cash equivalents and short-term investments totaled $94.8 million at December 31, 2013, compared to $54.4 million at December 31, 2012. In November 2013 the company completed the initial public offering of its common stock, issuing 7.9 million shares of common stock at a price of $11.00 per share. Net proceeds from the offering were approximately $78.0 million, after deducting underwriting discounts and commissions and offering expenses.Relypsa Inc (NASDAQ:RLYP) shares moved down -8.09% in last trading session and was closed at $30.01, while trading in range of $29.18-$33.28.Relypsa Inc (NASDAQ:RLYP) year to date performance is 20.04%.
Prothena Corporation plc (Nasdaq:PRTA) on Mar 3,2014 announced the promotion of Tara Nickerson, PhD, MBA, to Chief Business Officer. Dr. Nickerson is responsible for leading corporate and business development, as well as alliance management efforts at Prothena. Prior to this appointment, Dr. Nickerson held the position of Head of Corporate and Business Development at Prothena, where she was instrumental during Prothena’s demerger from Elan Corporation Limited (formerly Elan Corporation, plc) and led the team that developed Prothena’s previously announced worldwide collaboration with Roche to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena’s monoclonal antibody for the treatment of Parkinson’s disease and other related synucleinopathies.Prothena Corporation PLC (NASDAQ:PRTA) weekly performance is -20.78%. On last trading day company shares ended up $36.03.Prothena Corporation PLC (NASDAQ:PRTA) distance from 50-day simple moving average is 9.23%.